Sanofi (NYSE:SNY) posted its earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.74, Morningstar.com reports. The company had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s quarterly revenue was down 2.3% compared to the same quarter last year.
Sanofi (NYSE SNY) traded up 0.30% on Friday, reaching $47.55. 717,957 shares of the company traded hands. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The stock has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88. The stock’s 50-day moving average is $47.99 and its 200-day moving average is $46.11.
Institutional investors have recently bought and sold shares of the company. BLB&B Advisors LLC purchased a new position in Sanofi during the first quarter worth $202,000. Atria Investments LLC raised its position in Sanofi by 8.9% in the first quarter. Atria Investments LLC now owns 7,386 shares of the company’s stock worth $334,000 after buying an additional 602 shares during the last quarter. TNB Financial purchased a new position in Sanofi during the first quarter worth $1,329,000. Capstone Asset Management Co. raised its position in Sanofi by 6.0% in the first quarter. Capstone Asset Management Co. now owns 82,197 shares of the company’s stock worth $3,719,000 after buying an additional 4,635 shares during the last quarter. Finally, Gradient Investments LLC raised its position in Sanofi by 15,470.7% in the first quarter. Gradient Investments LLC now owns 6,384 shares of the company’s stock worth $289,000 after buying an additional 6,343 shares during the last quarter. Institutional investors and hedge funds own 9.96% of the company’s stock.
Several research firms have commented on SNY. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Argus increased their price objective on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Friday, June 2nd. Finally, Berenberg Bank lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.